Live Interview: Islet Cell Transplantation with Drs Gebe and Vernon

Event Details

Live Interview: Islet Cell Transplantation with Drs Gebe and Vernon

Time: August 22, 2013 from 1pm to 2pm
Location: TuDiabetes homepage
Website or Map: http://www.tudiabetes.org
Event Type: live interview, videochat
Organized By: Emily Coles
Latest Activity: Sep 17, 2013

Export to Outlook or iCal (.ics)

Event Description

This event already occurred.  Watch the recording here!

 

Summary of the Project
In a major collaborative effort led by matrix biologist Robert Vernon and immunologist John Gebe, scientists at the  Benaroya Research Institute are developing a Bioengineered Implant (BI) for treatment of type 1 diabetes (T1D) – an autoimmune disease. The BI will combine purified  islets of Langerhans  (the tiny, insulin-producing units of the pancreas) with innovative structural supports made of natural biomaterials.

The BI is designed to provide a controlled microenvironment that promotes the survival and function of the transplanted islets and includes: 1) a permeable extracellular matrix (ECM) hydrogel to provide physical support for the islets and ingrowing vasculature, 2) a sustained-release component that will deliver a set of bioactive compounds that promote islet survival, vascularization, and immunoprotection, and 3) a supportive scaffold to retain the islets, ECM hydrogel, and sustained-release component within a protective, unified structure. The combination of these design elements in a single device represents a novel approach to islet transplantation. The overall goal of this research is to produce a BI that can be implanted into patients in a minimally-invasive manner (perhaps under the skin) and which would eliminate the need for exogenous insulin therapy.

Description of study in researcher’s own words
Islet transplantation can be successful where the donor of the islets and the recipient of the transplant are genetically identical (as in syngeneic strains of mice). However, islet engraftment fails in human patients with T1D as a consequence of: 1) poor shortterm survival of the islets as a result of post-implantation stress, and 2) long-term immune-mediated rejection of the islets caused by tissue mismatches between donor and recipient (alloimmune rejection) and continuance of autoimmunity. Our working hypothesis for this project is that a spectrum of bioactive compounds that promote islet survival, islet vascularization, and protection of islets from host immune attack can be combined in a single device. Importantly, the influence of these compounds would be restricted to the BI and the region immediately surrounding it (using sustainedrelease technology), thereby limiting harmful systemic effects. Advanced versions of the BI might also be used as platforms for patient-derived stem cell transplantation, incorporating bioactive compounds that would promote the survival and differentiation of stem cells into insulin-producing cells.

Roles of the BRI researchers
Dr. Robert Vernon is a matrix biologist and bioengineer who provides the expertise in designing the BI and the system for sustained release of bioactive compounds. His understanding of the importance of revascularization to islet survival is instrumental to the success of this project. Dr. John Gebe is an immunologist with expertise in animal models of T1D. He conducts the hands-on testing of the device  in vivo and also determines which immunological systems can be targeted to promote long-term protection of islets from allo- and autoimmune rejection.

 

Comment Wall

Comment

RSVP for Live Interview: Islet Cell Transplantation with Drs Gebe and Vernon to add comments!

Join Diabetes community by Diabetes Hands Foundation: TuDiabetes

Comment by nel on August 21, 2013 at 6:15pm

I did share the link on my FB page /timeline

Comment by nel on August 20, 2013 at 10:26pm

Similar to the Canada Edmonton protocol ???http://www.islet.ca/candidate

Attending (10)

Might attend (2)

Not Attending (1)

Advertisement



REsources

From the Diabetes Hands Foundation blog...

#OpposeAB1893: California Bill that Burdens People with Diabetes on Insulin

A couple of days ago I learned that the California State Assembly is considering AB-1893 Sharps waste, which in (if approved) will mandate that: “Sharps sold to the general public in California shall be sold with a sharps waste container Read on! →

FDA Docket Extended! We Need You.

If you are new to diabetes advocacy in the traditional sense of the word, you may be thinking, “What the heck is a docket!?” I certainly was the first twenty times I heard it (yes it took that long). For Read on! →

Diabetes Hands Foundation Team

DHF TEAM

Manny Hernandez
(Co-Founder, Editor, has LADA)

Emily Coles
(Head of Communities, has type 1)

Mila Ferrer
(EsTuDiabetes Community Manager, mother of a child with type 1)

Mike Lawson
(Head of Experience, has type 1)

Corinna Cornejo
(Development Manager, has type 2)

Heather Gabel
(Administrative and Programs Assistant, has type 1)

DHF VOLUNTEERS


Lead Administrator
Bradford (has type 1)

Administrators
Lorraine (mother of type 1)
Marie B (has type 1)

Brian (bsc) (has type 2)

Gary (has type 2)

David (dns) (type 2)

 

LIKE us on Facebook

Spread the word

Loading…

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.

© 2014   A community of people touched by diabetes, run by the Diabetes Hands Foundation.

Badges  |  Contact Us  |  Terms of Service